Marvell Lumentum Deal: The $3.2bn Regulatory Break Fee and the Approvals Ahead
Marvell has agreed to buy Lumentum in an all-stock deal valuing it at $115bn, with closing not expected until 2028. We explain the merger agreement's approval conditions, its remedies covenant and the $3.2bn reverse break fee.
